AI Tenants Fill Lab Space as Property Values Fall 38% From 2022 Peak

Leasing activity climbed 63% from mid-2025 lows in four major markets, driven by artificial intelligence and quantum science companies seeking lab buildings, Newmark reports.

By the Family Office Real Estate Daily Desk·Monday, November 16, 2026·2 min read
Editorial summary of reporting byBisnowOur editorial standards →
The answer · checked against Bisnow

How much have lab building values fallen and what is driving new leasing demand in life sciences real estate?

Newmark's report on the lab real estate market finds that leasing activity in Boston, the Bay Area, Seattle, and San Diego reached 6.9 million SF through the first nine months of the year, with active tenant requirements up 63% from mid-2025 lows. AI and quantum science companies are driving new demand, but life sciences property values have fallen 38% from their 2022 peak and the national lab vacancy rate stands at 27%.

Key facts
  • Newmark's report found that the Boston, Bay Area, Seattle, and San Diego markets recorded 6.9M SF of leasing through the first nine months of the year.
  • The number of active tenant requirements in Boston, the Bay Area, Seattle, and San Diego is up 63% from the mid-2025 low point, according to Newmark.
  • Life sciences property values have fallen 38% from their peak in 2022 and are now 'well below' their late 2019 levels, according to Newmark's report citing the Green Street Commercial Property Price Index.
  • The national lab vacancy rate stood at 27% last quarter, and rents fell in eight of the 13 largest life sciences markets, Newmark found.
  • Biotech venture capital funding reached $11.5B through the third quarter of this year, already well above the levels reached in each of the four years before the pandemic, according to Newmark's report.
  • An index of publicly traded biotech companies has gained 124.6% since its April 2025 low, far outpacing the S&P 500, according to Newmark's report.
AI Tenants Fill Lab Space as Property Values Fall 38% From 2022 Peak
Image: editorial illustration · Story sourced from Bisnow

Landlords struggling with excess lab space in U.S. markets are finding new demand from artificial intelligence and quantum science companies, according to a report from Newmark. The Boston, Bay Area, Seattle and San Diego markets recorded 6.9 million square feet of leasing through the first nine months of this year. The number of active tenant requirements in those markets rose 63% from the mid-2025 low point.

AI companies Anthropic and Blitzy signed leases in Kendall Square this year, the report said. In the Bay Area, vacancy declined from 28.4% to 27.3%, which Newmark attributed to the outperformance of local AI and tech companies. Boston experienced meaningful AI growth, with leasing requirements in the first three quarters increasing 68% from 2025.

National lab vacancy stood at 27% in the third quarter. Rents fell in eight of the 13 largest life sciences markets. Life sciences property values have fallen 38% from their peak in 2022 and are now well below their late 2019 levels, citing the Green Street Commercial Property Price Index, Newmark said. The decline is steeper than the office market's pandemic-era drop.

Investor interest in life science assets has improved in recent quarters, but buyers remain selective, the report said. Occupiers are likely to continue to take advantage of depressed values through owner-user acquisitions. Alternative users are ramping up leasing activity within life sciences assets, helping to chip away at the overhang of space in select markets.

Biotech venture capital funding reached $11.5 billion through the third quarter of this year, already well above the levels reached in each of the four years before the pandemic. An index of publicly traded biotech companies has gained 124.6% since its April 2025 low, far outpacing the S&P 500. Merger and acquisition activity this year is the strongest it has been since 2021, the report said, indicating that Big Pharma companies are becoming far more active in the market.

Biomanufacturing has seen a significant increase, with Newmark saying the sector displays the most significant green shoots in the market. Big Pharma companies have poured hundreds of billions of dollars into U.S. manufacturing and research. Recent announcements include Eli Lilly's $6.5 billion commitment to Houston in September and BeOne's $300 million New Jersey expansion over the summer.

This positive momentum is expected to continue in the near term as select tenants seek to expand in core markets, the report said. Making substantial progress on bringing down vacancy and boosting values will require a surge in funding to the companies that lease lab space.

The Deployment Angle

Family Office Real Estate Daily Desk · our analysis, not the source's

The 38% value decline from 2022 peaks positions lab assets as distressed-capital opportunities, but deployment routes diverge sharply by tenant profile. Owner-user acquisitions favour direct ownership by family offices with operating subsidiaries in AI, quantum computing or biomanufacturing, where the building becomes infrastructure rather than a lease obligation. Platform capital alongside a stabilised landlord with demonstrated AI tenant sourcing makes sense in the Bay Area and Boston, where vacancy compression has begun. LP commitments to diversified life sciences funds carry execution risk until biotech funding sustains above $11.5 billion quarterly.

Underwrite the tenant's funding runway, not the property's historical occupancy. AI and quantum science lessees often burn capital faster than traditional pharma tenants, so cash reserves and venture backing matter more than credit ratings. The 63% rise in active requirements since mid-2025 signals pent-up demand, but eight of 13 markets still saw rent declines last quarter, meaning concession structures remain punitive. Price the gap between current net effective rents and the pro forma required to justify acquisition cost.

Biomanufacturing offers the cleanest path to stabilised income, given the hundreds of billions Big Pharma is deploying in U.S. manufacturing infrastructure. Eli Lilly's $6.5 billion Houston commitment and BeOne's $300 million New Jersey expansion are build-to-suit or long-lease opportunities that suit separate-account structures with single-tenant credit exposure. These deals trade development risk for lease certainty, and family offices with construction-management capability can co-invest on the equity side of a programmatic JV with a life sciences developer.

Avoid broad-market opportunistic funds targeting lab conversions in secondary cities where the 27% national vacancy rate overstates distress. The recovery is concentrated in four markets, and the Green Street index shows values now sit below late 2019 levels, meaning basis alone does not create alpha. The selective buyer behaviour Newmark describes reflects the need for tenant-specific underwriting and local life sciences networks, which most generalist value-add managers lack.

Questions this story answers

01How far have life sciences property values fallen from their peak?

Newmark's report, citing the Green Street Commercial Property Price Index, says life sciences property values have fallen 38% from their 2022 peak and are now 'well below' their late 2019 levels. Newmark notes the decline is steeper than the office market's pandemic-era drop.

02What is driving new leasing demand in lab buildings?

According to Newmark, requirements from AI and quantum science companies are increasing as landlords try to fill space left behind by traditional lab users. In Boston, AI companies Anthropic and Blitzy signed leases in Kendall Square, and leasing requirements in the first three quarters increased 68% from 2025.

03What is the current lab vacancy rate and which markets are seeing improvement?

Newmark found the national lab vacancy rate stood at 27% last quarter. In the Bay Area specifically, Newmark attributes a vacancy decline from 28.4% to 27.3% to the outperformance of local AI and tech companies.

04Are Big Pharma companies investing in U.S. lab and manufacturing real estate?

According to Newmark's report, Big Pharma companies have poured hundreds of billions of dollars into U.S. manufacturing and research. Recent announcements include Eli Lilly's $6.5B commitment to Houston in September and BeOne's $300M New Jersey expansion over the summer.

05What does investor sentiment look like for life sciences real estate right now?

Newmark's report says investor interest in life science assets has improved in recent quarters, but buyers remain selective. Newmark also notes that occupiers are likely to continue taking advantage of depressed values through owner-user acquisitions.

Original reporting
Bisnow
Read the original at Bisnow →
life-sciencesai-tenantslab-buildingsdistressed-assetsbiomanufacturing
Peer Network · By Invitation

The Thesis Exchange

Share an investment thesis in confidence. We pair you anonymously with up to two other family offices running adjacent strategies. Reviewed by Gallium's editorial team. No vendor pitch.